FLEMINGTON, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, today entered into a collaboration agreement with BioAlliance Pharma SA for the development and commercialization of NovaDel’s ondansetron oral spray (OS) for Europe. Ondansetron is the leading 5-HT3 antagonist to prevent nausea and vomiting after chemotherapy, radiation and surgery. Upon successful development and approval, NovaDel believes ondansetron OS could be the first antiemetic to be available in Europe in an oral spray form. BioAlliance and NovaDel anticipate collaborating in the completion of development activities for Europe, with BioAlliance responsible for regulatory and commercialization activities.
